NCT00274352 - A Study of Adalimumab to Treat Sarcoidosis of the Skin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Sarcoidosis

Interventions

DRUG

adalimumab

Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.

Trial Locations (1)

23507

Virginia Clinical Research, Inc., Norfolk